Why Zevra Therapeutics Stock Zoomed 21% Higher Today
2026-03-10 18:17:11 ET
Zevra Therapeutics (NASDAQ: ZVRA) was one of the healthier companies on the stock exchange on Tuesday. Investors eagerly piled into its shares following the commercial-stage biotech 's latest earnings release, leaving Zevra with a slightly over 21% gain that day.
Zevra's final set of 2025 earnings was released just after market close Monday, revealing that the company's net revenue was slightly over $34 million in the fourth quarter. That was 44% higher than the same period of 2024. Better, the company flipped to a net profit under generally accepted accounting principles (GAAP) of $12.2 million ($0.19) per share, from the year-ago loss of $35.7 million.
Image source: Getty Images.
NASDAQ: ZVRA
ZVRA Trading
-6.76% G/L:
$10.075 Last:
2,626,935 Volume:
$10.76 Open:
